Compare ONCY & ERH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONCY | ERH |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.5M | 107.4M |
| IPO Year | 2002 | N/A |
| Metric | ONCY | ERH |
|---|---|---|
| Price | $0.82 | $11.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.33 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 28.9K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.85% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,505.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $11.50 |
| 52 Week High | $1.51 | $13.07 |
| Indicator | ONCY | ERH |
|---|---|---|
| Relative Strength Index (RSI) | 47.69 | 38.81 |
| Support Level | $0.78 | $11.59 |
| Resistance Level | $1.08 | $11.96 |
| Average True Range (ATR) | 0.04 | 0.15 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 70.56 | 8.19 |
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
Allspring Utilities and High Income Fund is a diversified closed-end management investment company. Its investment objective is to seek a high level of current income and moderate capital growth, with an emphasis on providing tax-advantaged dividend income. The company allocates a majority of its total assets to a sleeve that places a focus on common, preferred, and convertible preferred stocks of utility companies and the rest of its total assets to a sleeve of U.S. dollar denominated below investment grade (high yield) debt.